| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Exicure, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.48 |
| 52 Week High | US$4.23 |
| 52 Week Low | US$1.30 |
| Beta | 1.24 |
| 11 Month Change | -11.90% |
| 3 Month Change | 6.47% |
| 1 Year Change | -54.60% |
| 33 Year Change | -99.09% |
| 5 Year Change | -99.57% |
| Change since IPO | -99.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2H0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.2% | 0.2% |
| 1Y | -54.6% | -16.1% | 7.6% |
Return vs Industry: 2H0 underperformed the German Biotechs industry which returned -16.1% over the past year.
Return vs Market: 2H0 underperformed the German Market which returned 7.6% over the past year.
Price Volatility
| 2H0 volatility | |
|---|---|
| 2H0 Average Weekly Movement | 58.4% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2H0's share price has been volatile over the past 3 months.
Volatility Over Time: 2H0's weekly volatility has increased from 36% to 58% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 5 | Paul Kang | www.exicuretx.com |
Exicure, Inc. does not have significant operations. previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Exicure, Inc. Fundamentals Summary
| 2H0 fundamental statistics | |
|---|---|
| Market cap | €6.27m |
| Earnings (TTM) | -€7.35m |
| Revenue (TTM) | €449.75k |
13.9x
P/S Ratio-0.9x
P/E RatioIs 2H0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2H0 income statement (TTM) | |
|---|---|
| Revenue | US$500.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$500.00k |
| Other Expenses | US$8.67m |
| Earnings | -US$8.17m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.72 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,634.40% |
| Debt/Equity Ratio | 62.0% |
How did 2H0 perform over the long term?
See historical performance and comparison